Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CERo Therapeutics Holdings, Inc. (CERO)
USD0.01
0.00 (-8.08%)
US OTC Healthcare Biotechnology
Address
201 Haskins Way 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Christopher Ehrlich
Website
cero.bio
IPO
2021-11-30
CIK 1870404 ISIN US71902K4022
Also trades on
Other OTC · CERO (USD)
Other OTC · CEROW (USD)
Description
CERo Therapeutics Holdings, Inc. is a biotech firm dedicated to pioneering advanced engineered T-cell immunotherapies for the treatment of various cancers. Their leading therapeutic candidate, CER-1236, is an autologous T-cell therapy currently in development, aimed at addressing both blood cancers (hematologic malignancies) and solid tumors. This company was founded in 2021 and is headquartered in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
0.00 (-8.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
835.5K
Beta
0.12
Float Shares
1.18M
Free Float %
97.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.50% | -11.35% | -11.35% | -40.24% | -64.54% | -60.28% | -99.78% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (1 ratings, all time)
Hold
Price Targets & DCF
Current price
0.01
DCF (Levered)
0.23
+1,805.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-95.25
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-228.7% Q1'26: +93.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +203.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+3,401.7% Q1'26: +16,678.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.04× Q1'26: -0.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 EPS Ana. |
Dec 2027 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
52.32M
52.32M – 52.32M
|
131.86M
131.86M – 131.86M
+152.0% YoY
|
| EBITDA |
-6.57M
|
-17.38M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-7.73M
|
-18.46M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-7.73M
est: -4.24M (-82.5%)
|
-19.92M
est: -18.15M (-9.8%)
|
-10.56M
-10.56M – -10.56M
+41.8% YoY
|
-13.81M
-13.81M – -13.81M
-30.7% YoY
|
-11.66M
-11.66M – -11.66M
+15.6% YoY
|
-11.84M
-11.84M – -11.84M
-1.6% YoY
|
-9.98M
-9.98M – -9.98M
+15.7% YoY
|
| SGA |
8.99M
|
8.08M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-6.87
est: -35.08 (+80.4%)
|
-22.58
est: -4.29 (-426.3%)
|
-2.50
-2.50 – -2.50
+41.8% YoY
|
-3.26
-3.26 – -3.26
-30.7% YoY
|
-2.76
-2.76 – -2.76
+15.6% YoY
|
-2.80
-2.80 – -2.80
-1.6% YoY
|
-2.36
-2.36 – -2.36
+15.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Gary Yeung | 22.62M | 15.00% | — | 22.62M | — | — | IN | Delaware | 2024-11-14 | ↗ |
| 2 | LLC) | 22.62M | 15.00% | — | 22.62M | — | — | PN | Delaware | 2024-11-14 | ↗ |
| 3 | Mitchell Kossar | 22.62M | 15.00% | — | 22.62M | — | — | IN | Delaware | 2024-11-14 | ↗ |
| 4 | YK Bioventures Opportunities GP I, LLC (F/K/A YK Bioventures, LLC) | 22.62M | 15.00% | — | 22.62M | — | — | OO | Delaware | 2024-11-14 | ↗ |
| 5 | Brian G. Atwood | 19.73M | 13.40% | 125.0K | 19.61M | 125.0K | 19.61M | IN | — | 2024-10-30 | ↗ |
| 6 | Lynne H. Edminster | 19.61M | 13.30% | — | 19.61M | — | 19.61M | IN | — | 2024-10-30 | ↗ |
| 7 | Trust dtd 4-2-2000 | 19.61M | 13.30% | — | 19.61M | — | 19.61M | OO | — | 2024-10-30 | ↗ |
| 8 | Lawrence Corey | 8.53M | 5.70% | 8.53M | — | 8.53M | — | IN | United States | 2024-12-13 | ↗ |
| 9 | SMS Revocable Trust | 996.7K | 6.70% | 996.7K | — | 996.7K | — | OO | U.S.A. | 2024-11-20 | ↗ |
| 10 | Stuart Sloan | 996.7K | 6.70% | 996.7K | — | 996.7K | — | IN | U.S.A. | 2024-11-20 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
11.68M
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+11,680,894
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-04 | Francois Eric | Director | A-Award | A | Stock Option (Right to Buy) | 1,823,278 | 0.06 | 100.3K | 1,823,278 | D | ↗ |
| 2026-02-13 | Francois Eric | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-01-07 | Rolfe Lindsey | Director | A-Award | A | Stock Option (Right to Buy) | 690,900 | 0.06 | 38.0K | 690,900 | D | ↗ |
| 2026-01-07 | Pierce Kristen | Officer | A-Award | A | Stock Option (Right to Buy) | 1,612,099 | 0.06 | 88.7K | 1,612,099 | D | ↗ |
| 2026-01-07 | Patel Shami | Director | A-Award | A | Stock Option (Right to Buy) | 690,900 | 0.06 | 38.0K | 690,900 | D | ↗ |
| 2026-01-07 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 690,900 | 0.06 | 38.0K | 690,900 | D | ↗ |
| 2026-01-07 | KUCHARCHUK ANDREW ALBERT | Officer | A-Award | A | Stock Option (Right to Buy) | 1,162,099 | 0.06 | 63.9K | 1,162,099 | D | ↗ |
| 2026-01-07 | Ehrlich Christopher B | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 4,530,997 | 0.06 | 249.2K | 4,530,997 | D | ↗ |
| 2026-01-07 | Byrnes Michael | Director | A-Award | A | Stock Option (Right to Buy) | 690,900 | 0.06 | 38.0K | 690,900 | D | ↗ |
| 2026-01-07 | ATWOOD BRIAN G | Director | A-Award | A | Stock Option (Right to Buy) | 1,612,099 | 0.06 | 88.7K | 1,612,099 | D | ↗ |
| 2025-05-30 | Rolfe Lindsey | Director | A-Award | A | Stock Option (Right to Buy) | 9,326 | 0.45 | 4.2K | 9,326 | D | ↗ |
| 2025-05-30 | Pierce Kristen | Officer | A-Award | A | Stock Option (Right to Buy) | 154,841 | 0.45 | 69.0K | 154,841 | D | ↗ |
| 2025-05-30 | Patel Shami | Director | A-Award | A | Stock Option (Right to Buy) | 11,693 | 0.45 | 5.2K | 11,693 | D | ↗ |
| 2025-05-30 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 9,326 | 0.45 | 4.2K | 9,326 | D | ↗ |
| 2025-05-30 | KUCHARCHUK ANDREW ALBERT | Officer | A-Award | A | Stock Option (Right to Buy) | 152,500 | 0.45 | 67.9K | 152,500 | D | ↗ |
| 2025-05-30 | Ehrlich Christopher B | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 61,843 | 0.45 | 27.5K | 61,842 | D | ↗ |
| 2025-05-30 | Byrnes Michael | Director | A-Award | A | Stock Option (Right to Buy) | 9,326 | 0.45 | 4.2K | 9,326 | D | ↗ |
| 2025-05-30 | ATWOOD BRIAN G | Director | A-Award | A | Stock Option (Right to Buy) | 122,549 | 0.45 | 54.6K | 122,549 | D | ↗ |
| 2025-03-31 | ATWOOD BRIAN G | Director | M-Exempt | A | Common Stock | 294,460 | 0.00 | 29.45 | 490,534 | I | ↗ |
| 2025-03-04 | Ehrlich Christopher B | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 119,486 | 1.43 | 170.9K | 119,486 | D | ↗ |
| 2025-02-24 | Rolfe Lindsey | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.8K | 255,000 | D | ↗ |
| 2025-02-24 | Patel Shami | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.1K | 255,000 | D | ↗ |
| 2025-02-24 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.8K | 255,000 | D | ↗ |
| 2025-02-24 | Ehrlich Christopher B | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,275,000 | 0.10 | 127.5K | 2,550,000 | D | ↗ |
| 2025-02-24 | Byrnes Michael | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.8K | 255,000 | D | ↗ |
| 2025-02-24 | ATWOOD BRIAN G | Director | A-Award | A | Stock Option (Right to Buy) | 254,000 | 0.10 | 25.4K | 508,000 | D | ↗ |
| 2025-02-07 | ATWOOD BRIAN G | Director | A-Award | A | Warrant to Purchase Shares of Common Stock | 306,120 | 1.96 | 600.0K | 306,120 | D | ↗ |
| 2024-12-13 | YK Bioventures Opportunities GP I, LLC | 10% Owner | S-Sale | D | Common Stock | 2,998,908 | 0.06 | 179.9K | 13,005,169 | I | ↗ |
| 2024-12-12 | YK Bioventures Opportunities GP I, LLC | 10% Owner | S-Sale | D | Common Stock | 1,614,541 | 0.07 | 113.0K | 16,004,077 | I | ↗ |
| 2024-12-11 | YK Bioventures Opportunities GP I, LLC | 10% Owner | S-Sale | D | Common Stock | 1,343,801 | 0.08 | 107.5K | 17,618,618 | I | ↗ |
| 2024-12-10 | YK Bioventures Opportunities GP I, LLC | 10% Owner | S-Sale | D | Common Stock | 1,570,947 | 0.09 | 141.4K | 18,962,419 | I | ↗ |
| 2024-12-09 | YK Bioventures Opportunities GP I, LLC | 10% Owner | S-Sale | D | Common Stock | 850,543 | 0.11 | 93.6K | 20,533,366 | I | ↗ |
| 2024-12-06 | YK Bioventures Opportunities GP I, LLC | 10% Owner | S-Sale | D | Common Stock | 1,236,874 | 0.12 | 148.4K | 21,383,909 | I | ↗ |
| 2024-12-02 | Rolfe Lindsey | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.8K | 127,500 | D | ↗ |
| 2024-12-02 | Patel Shami | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.1K | 127,500 | D | ↗ |
| 2024-12-02 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.8K | 127,500 | D | ↗ |
| 2024-12-02 | Ehrlich Christopher B | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,275,000 | 0.10 | 127.5K | 1,275,000 | D | ↗ |
| 2024-12-02 | Byrnes Michael | Director | A-Award | A | Stock Option (Right to Buy) | 127,500 | 0.10 | 12.8K | 127,500 | D | ↗ |
| 2024-12-02 | ATWOOD BRIAN G | Director | A-Award | A | Stock Option (Right to Buy) | 254,000 | 0.10 | 25.4K | 254,000 | D | ↗ |
| 2024-10-11 | Patel Shami | Director | — | — | Class A Common Stock | 0 | 0.00 | — | 1,010,254 | I | ↗ |
| 2024-10-10 | YK Bioventures Opportunities GP I, LLC | 10% Owner | S-Sale | D | Common Stock | 3,250,000 | 0.10 | 325.0K | 22,620,783 | I | ↗ |
| 2024-10-01 | Pierce Kristen | Officer | — | — | Stock Option (Right to Buy) | 659 | 10.00 | 6.6K | 0 | D | ↗ |
| 2024-10-01 | KUCHARCHUK ANDREW ALBERT | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-30 | Ehrlich Christopher B | Director / Officer | D-Return | D | Stock Option (Right to Buy) | 572,182 | 1.77 | 1.01M | 0 | D | ↗ |
| 2024-09-30 | ATWOOD BRIAN G | Director | D-Return | D | Stock Option (Right to Buy) | 1,317,956 | 1.77 | 2.33M | 0 | D | ↗ |
| 2024-09-26 | YK Bioventures Opportunities GP I, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 25,870,783 | I | ↗ |
| 2024-09-25 | SLOAN STUART M | 10% Owner | S-Sale | D | Common Stock, $0.0001 par value per share | 532,486 | 0.10 | 55.5K | 21,067,956 | I | ↗ |
| 2024-09-25 | LAPORTE KATHLEEN | Director | M-Exempt | D | Series A Convertible Preferred Stock | 50 | 0.00 | — | 0 | D | ↗ |
| 2024-09-25 | Ehrlich Christopher B | Director / Officer | M-Exempt | A | Common Stock | 5,312,983 | 1,000.00 | 5.31B | 5,791,808 | D | ↗ |
| 2024-09-25 | ATWOOD BRIAN G | Director | M-Exempt | A | Common Stock | 19,358,578 | 1,000.00 | 19.36B | 19,607,313 | I | ↗ |
| 2024-09-24 | SLOAN STUART M | 10% Owner | — | — | Common Stock, $0.0001 par value per share | 0 | 0.00 | — | 21,600,442 | I | ↗ |
| 2024-06-28 | Carter Charles Ross | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.30 | 30.0K | 100,000 | — | ↗ |
| 2024-03-25 | Rolfe Lindsey | Director | A-Award | A | Stock Option (Right to Buy) | 112,500 | 1.77 | 199.1K | 112,500 | — | ↗ |
| 2024-03-25 | Rapaport Robyn | Director | A-Award | A | Stock Option (Right to Buy) | 112,500 | 1.77 | 199.1K | 112,500 | — | ↗ |
| 2024-03-25 | LAPORTE KATHLEEN | Director | A-Award | A | Stock Option (Right to Buy) | 112,500 | 1.77 | 199.1K | 112,500 | — | ↗ |
| 2024-03-25 | Ehrlich Christopher B | Director | A-Award | A | Stock Option (Right to Buy) | 572,182 | 1.77 | 1.01M | 572,182 | — | ↗ |
| 2024-03-25 | Corey Daniel | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 856,671 | 1.77 | 1.52M | 856,671 | — | ↗ |
| 2024-03-25 | Carter Charles Ross | Officer | A-Award | A | Stock Option (Right to Buy) | 395,387 | 1.77 | 699.8K | 395,387 | — | ↗ |
| 2024-03-25 | Byrnes Michael | Director | A-Award | A | Stock Option (Right to Buy) | 112,500 | 1.77 | 199.1K | 112,500 | — | ↗ |
| 2024-03-25 | ATWOOD BRIAN G | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,317,956 | 1.77 | 2.33M | 1,317,956 | — | ↗ |
| 2024-03-15 | Patel Shami | Director | — | — | Warrants | 264,998 | 11.50 | 3.05M | 0 | I | ↗ |
| 2024-02-14 | Rolfe Lindsey | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-14 | Rapaport Robyn | Director | — | D | Common Stock | 0 | 0.00 | — | 50,000 | — | ↗ |
| 2024-02-14 | PHOENIX BIOTECH SPONSOR, LLC | 10% Owner | J-Other | D | Series A Convertible Preferred Stock | 1,555 | 10.00 | 15.6K | 0 | — | ↗ |
| 2024-02-14 | Loewy Caroline M | Director | J-Other | A | Class A Common Stock | 5,828 | 0.00 | — | 5,828 | — | ↗ |
| 2024-02-14 | LAPORTE KATHLEEN | Director | J-Other | A | Common Stock | 5,828 | 0.00 | — | 5,828 | — | ↗ |
| 2024-02-14 | Kosacz Barbara | Director | J-Other | A | Class A Common Stock | 5,828 | 0.00 | — | 5,828 | — | ↗ |
| 2024-02-14 | Geffken Daniel E. | Officer | J-Other | A | Class A Common Stock | 10,002 | 0.00 | — | 10,002 | — | ↗ |
| 2024-02-14 | Fisher Douglas Carl | Officer | J-Other | A | Class A Common Stock | 43,300 | 0.00 | — | 43,300 | — | ↗ |
| 2024-02-14 | Ehrlich Christopher B | Director | J-Other | A | Common Stock | 3,600 | 0.00 | — | 3,600 | — | ↗ |
| 2024-02-14 | Corey Daniel | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 3,399 | — | ↗ |
| 2024-02-14 | Carter Charles Ross | Officer | — | D | Series A Convertible Preferred Stock | 5,000 | 10.00 | 50.0K | 0 | — | ↗ |
| 2024-02-14 | Byrnes Michael | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-14 | ATWOOD BRIAN G | Director / Officer | J-Other | A | Common Stock | 125,000 | 0.00 | — | 125,000 | — | ↗ |
Executive team
Top executives
Shares Outstanding
1.21M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christopher Ehrlich | Chief Executive Officer & Chair | 770.3K | male |
| Andrew Albert Kucharchuk | Chief Financial Officer | 443.7K | male |
| Kristen Pierce | Chief Development Officer | 360.0K | — |
| Lawrence Corey | Co-founder & Head of Scientific Advisory Board | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CERO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
